Depo-Transfer, a popular contraceptive injection, has been linked to a significant risk of developing meningioma brain tumors. A March 2024 study published in the British Medical Journal found that long-term use of the drug could increase the risk of these tumors by over 5 times compared to non-users.
Pfizer, the manufacturer, failed to include warnings about this serious risk on the drug's US label, despite similar warnings being present in other countries for years. Women who have been diagnosed with brain tumors after using Depo-Transfer are now seeking justice and compensation for their injuries.
To participate in the Depo-Transfer litigation, potential plaintiffs generally need to meet the following criteria:
Used Depo-Transfer birth control shot (typically at least 2 injections).
Diagnosed with a meningioma or another type of brain tumor.
Did not receive a warning about the risk of brain tumors.
Successful claims will need to proivde:
Proof of Use: Medical records or pharmacy records showing Depo-Transfer injections.
Proof of Injury: Medical records confirming a diagnosis of meningioma or brain tumor.
The Depo-Transfer lawsuit alleges that Pfizer failed to warn users about the increased risk of developing meningioma brain tumors from using the contraceptive injection. Recent studies have shown a significant link between long-term use of Depo-Transfer and these tumors.
You may be eligible if you used the Depo-Transfer birth control shot (typically at least two injections), were subsequently diagnosed with a meningioma or other brain tumor, and did not receive a warning about this specific risk.
A meningioma is a type of tumor that forms on membranes that cover the brain and spinal cord just inside the skull. While often non-cancerous, they can be serious and require surgery or other treatment depending on their size and location.
Deadlines to file vary by state. However, due to the "discovery rule," you may still be able to file even if you used the drug years ago, as the link between Depo-Transfer and brain tumors was not widely known until recently. It is best to consult with a lawyer to determine your specific deadline.
The primary defendant is Pfizer Inc., the manufacturer of Depo-Transfer. Other potential defendants include authorized generic distributors like Viatris, Greenstone, LLC, and Prasco Labs.
Case Review Form